[ad_1]
December 15, 2025
1 min read
Key takeaways:
- Patients who underwent osteochondral allograft transplantation had improved elbow function.
- At 1- and 2-year follow-up, rate of return to sport was 82% and 96%, respectively.
Osteochondral allograft transplantation may be an effective treatment for pediatric patients with elbow osteochondritis dissecans, according to data recently published in The American Journal of Sports Medicine.
“The results of this study support this treatment as standard-of-care for children with elbow [osteochondritis dissecans (OCD)],” Crystal A. Perkins, MD, pediatric orthopedic surgeon at Children’s Healthcare of Atlanta, told Healio. “This evidence allows surgeons to have an informed discussion with patients and families with regards to anticipated surgical outcomes and ability to return to sports.”
Data were derived from Perkins CA, et al. Am J Sports Med. 2025;doi:10.1177/03635465251366903.
Perkins and colleagues at Children’s Healthcare of Atlanta prospectively collected data from 28 elbows in 26 pediatric patients (mean age, 13.5 years) with unstable OCD of the capitellum who were treated with primary fresh osteochondral allograft transplantation.
Crystal A. Perkins
Outcome measures included postoperative MRI graft incorporation, as well as preoperative and postoperative patient-reported outcome measures and return to sports with minimum 2-year follow-up.
Overall, Perkins and colleagues found patients had a return to sport rate of 82% at 1-year and 96% at 2-years.
Because patients and families are interested in long-term functional outcomes, Perkins said they will continue to follow patients to collect mid-term and long-term outcomes as well as enroll more patients for a larger series follow-up.
“An important message we try to convey to patients and families is the importance of taking your pediatric and adolescent athlete to a pediatric sports medicine expert. This prospective research study highlights our surgeon’s expertise and commitment to high-quality care of youth athletes.”
For more information:
Crystal A. Perkins, MD, may be contacted at Crystal.perkins@choa.org.
Sources/Disclosures
Source:
Perkins CA, et al. Am J Sports Med. 2025;doi:10.1177/03635465251366903.
Reference:
Disclosures:
Perkins reports no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
[ad_2]
Source link
